Draft Guidance: Judicious Use of Medically Important Antimicrobial Drugs in Food-Producing Animals; Availability

Federal Register: June 29, 2010 (Volume 75, Number 124)

Notices

Page 37450-37451

From the Federal Register Online via GPO Access [wais.access.gpo.gov]

DOCID:fr29jn10-77

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Docket No. FDA-2010-D-0094

Draft Guidance: The Judicious Use of Medically Important

Antimicrobial Drugs in Food-Producing Animals; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a draft guidance (209) entitled ``The

Judicious Use of Medically Important Antimicrobial Drugs in Food-

Producing Animals.'' This draft guidance is intended to inform the public of FDA's current thinking on the use of medically important antimicrobial drugs in food-producing animals.

DATES: Although you can comment on any guidance at any time (see 21

CFR 10.115(g)(5)), to ensure that the agency considers your comment on this draft guidance before it begins work on the final version of the guidance, submit either electronic or written comments on the draft guidance by August 30, 2010.

ADDRESSES: Submit written requests for single copies of the guidance to the Communications Staff (HFV-12), Center for Veterinary Medicine,

Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855.

Send one self-addressed adhesive label to assist that office in processing your requests. Additional copies of this guidance are available from the Office of Communication, Outreach and Development

(OCOD) (HFM-40), Food and Drug Administration, 1401 Rockville Pike, suite 200N, Rockville, MD 20852-1448, or by calling 1-800-835-4709 or 301-827-1800, or e-mail: ocod@fda.hhs.gov. See the SUPPLEMENTARY

INFORMATION section for electronic access to the draft guidance document.

Submit electronic comments on the draft guidance to http:// www.regulations.gov. Submit written comments on the draft guidance to the Division of Dockets Management (HFA-305), Food and Drug

Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: William T. Flynn, Center for

Veterinary Medicine (HFV-1), Food and Drug Administration, 7519

Standish Pl., Rockville, MD 20855, 240-276-9084, e-mail: william.flynn@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

1. Background

   FDA is announcing the availability of a draft guidance

   (209) entitled ``The Judicious Use of Medically Important

   Antimicrobial Drugs in Food-Producing Animals.'' Antimicrobial drugs have been widely used in human and veterinary medicine for more than 50 years, with tremendous benefits to both human and animal health. The development of resistance to this important class of drugs, and the resulting loss of their effectiveness as antimicrobial therapies, poses a serious public health threat. Misuse and overuse of antimicrobial drugs creates selective evolutionary pressure that enables antimicrobial resistant bacteria to increase in numbers more rapidly than antimicrobial susceptible bacteria and thus increases the opportunity for individuals to become infected by resistant bacteria.

   Because antimicrobial drug use contributes to the emergence of drug resistant organisms, these important drugs must be used judiciously in both animal and human medicine to slow the development of resistance.

   Using these drugs judiciously means that unnecessary or inappropriate use should be avoided. Although efforts to assure judicious use should be directed at all uses of antimicrobial drugs, the focus of this document is on the use of medically important antimicrobial drugs in food-producing animals.

   In regard to the use of antimicrobial drugs in animals, concerns have been raised by the public and components of the scientific and public health communities that a significant contributing factor to antimicrobial resistance is the use of medically important antimicrobial drugs in food-producing animals for production or growth- enhancing purposes. This document summarizes some of the key scientific reports on the use of antimicrobial drugs in animal agriculture and outlines FDA's current thinking on strategies for assuring that medically important antimicrobial drugs are used judiciously in food- producing animals in order to help minimize antimicrobial resistance development.

   Based on a consideration of the available scientific information,

   FDA is making a number of recommendations regarding the appropriate or judicious use of medically important antimicrobial drugs in food- producing animals. These recommendations include phasing in such measures as follows: (1) Limiting medically important antimicrobial drugs to uses in food-producing animals that are considered necessary for assuring

   Page 37451

   animal health and (2) limiting such drugs to uses in food-producing animals that include veterinary oversight or consultation. Developing strategies for reducing antimicrobial resistance is critically important for protecting both public and animal health. Collaboration involving both the public and animal health communities on the development and implementation of such strategies is needed to assure that the public health is protected while also assuring that the health needs of animals are addressed.

   This draft guidance discusses FDA's general public health concerns regarding the potential impact of certain uses of medically important antimicrobial drugs in food-producing animals on the development of antimicrobial resistance, and provides two broad recommendations regarding such use. The agency intends to issue further guidance in the near future to provide more specific information on approaches for implementing the recommendations outlined in this draft guidance.

2. Significance of Guidance

   This level 1 draft guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The draft guidance, when finalized, will represent the agency's current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations.

3. Paperwork Reduction Act of 1995

   FDA concludes that there are no collections of information under the Paperwork Reduction Act of 1995.

4. Comments

   Interested persons may submit to the Division of Dockets Management

   (see ADDRESSES) either electronic or written comments regarding this document. It is only necessary to send one set of comments. It is no longer necessary to send two copies of mailed comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets

   Management between 9 a.m. and 4 p.m., Monday through Friday.

4. Electronic Access

   Persons with access to the Internet may obtain the draft guidance at either http://www.fda.gov/AnimalVeterinary/default.htm or http:// www.regulations.gov.

   Dated: June 10, 2010.

   Leslie Kux,

   Acting Assistant Commissioner for Policy.

   FR Doc. 2010-15289 Filed 6-28-10; 8:45 am

   BILLING CODE 4160-01-S